Elutia (ELUT) investor relations material

Technology and product overview

• Drug-eluting biologic platform combines a biological matrix with locally released antibiotics to prevent postoperative infections in soft tissue surgeries.

• EluPro, launched for pacemaker stabilization, achieved an $18 million run rate within ten months before being sold for $88 million.

• The same technology is now being applied to NXT-41x for breast reconstruction, targeting a significant unmet need.

Market opportunity and clinical need

• Breast reconstruction represents a $1.5 billion U.S. market with 162,000 procedures annually, most using biological mesh.

• Postoperative infection rates in breast reconstruction are 15%-20%, significantly higher than in pacemaker procedures.

• Each infection adds nearly 10 days to hospital stays and costs $48,000, not covered by payers, impacting hospital margins.

Product differentiation and clinical rationale

• Standard antibiotics are ineffective post-mastectomy due to loss of local blood supply; local antibiotic delivery via mesh addresses this gap.

• NXT-41x uses a sustained-release coating of rifampin and minocycline, providing local, non-systemic infection control.

• The product is cost-neutral for hospitals, replacing standard mesh with an antibiotic-enhanced version.